Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

Hood College to Lead Lobster Research in Maine with NSF Grant

News Image

Hood College is the lead on an $860,000 multi-institutional collaboration with the Bigelow Laboratory for Ocean Sciences, the University of New England, and the Maine Department of Marine Resources, funded by the National Science Foundation.

Eric Annis, Ph.D., associate professor of biology at Hood and lead scientist on the project, will take two undergraduate summer interns to study lobsters in the Gulf of Maine in each year of the project. Hood will receive $290,000 to support this project, covering instrumentation for measuring the oxygen consumption by individual lobster larvae and temperature control for seawater tanks that will enhance their ability to conduct research related to climate change.

Lobsters start their life as larvae that are drifting in the water and then they settle on the ocean floor to grow into adults. Where lobster larvae settle and how many survive is determined in part by the temperature of the water. Water that is too cold or too hot can reduce survival or drive them away. Researchers don’t know much about the temperature range that the larvae can tolerate. The research conducted by Annis and company will help define the thermal range and will link temperature sensitivity to where the larvae settle. The success of the larvae determines the number of harvestable adult lobsters, and this research will improve the understanding of how climate change will impact this economically and ecologically important species.

“This lobster fishery is one of the most valuable in North America with an estimated value that typically exceeds $500 million per year,” said Annis. “Due to their large size and abundance in the Gulf of Maine, lobsters also play an important role in food web of the ecosystem.”

This NSF grant is a direct result of the research Annis completed in spring 2019 through a grant from the Maine Department of Marine Resources, which laid the groundwork for this new study. Annis developed the NSF grant proposal for the new research with support from a Hood College Board of Associates’ McCardell Professional Development Grant in 2019.

“I’m really excited about this project because we have a talented group of researchers from two undergraduate colleges, a leading marine research institution and a state agency collaborating to answer fundamental questions about how lobster larvae will respond to climate change,” said Annis. “This collaborative atmosphere, coupled with exciting travel and hands-on research, will generate truly transformative experiences for our students. This will provide fantastic opportunities to engage our undergraduate students in high-caliber scientific research in coastal Maine.”

Hood College is an independent, liberal arts college, offering more than 25 bachelor’s degrees, four pre-professional programs, 19 master’s degrees programs, two doctorates and 10 post-baccalaureate certificates. Located in historic Frederick, near Washington, D.C., Baltimore and the I-270 technology corridor, Hood gives students access to countless internships and research opportunities.

Share article on social media or email:

Free Online Education and Distance Learning

At the time of our current COVID – 19 crisis and the shutdown of most schools and colleges there is a need for free online educational courses and distant learning. is a curated directory for these free online education resources. This curated directory has hand-selected and aggregated the best free videos and websites for over 50 high school and college topics. There are separate Top 20 directories for literature, philosophy, chemistry, calculus, computer science, art history, and more than 50 other courses. Most of the major universities in the United States have video lectures of some of their courses free online, such as those available on Coursera and EdX. Khan Academy, Crash Course, YouTube, TED lectures, many other private and government websites offer free educational videos and websites. A curated directory addresses the problem of information overload and is usually a better guide to these resources than the search engines. At the graduate level, materials for the first two years of medical school have been selected and aggregated free online at is a directory of free resources for children. These are all great free educational resources for both teachers and students.

Access to education is also a global issue of our times. Learning English is the gateway to all of these free world-class educational materials on the internet. is a curated directory of the best free videos and websites for learning English as a second language (ESL). There is also a program for learning one’s first 200 words of English using Google Translate in 103 different languages. There are separate directories for phonics, vocabulary, grammar, listening, conversation, free online courses, and testing options. There is a very large need for these free resources both among a diverse immigrant population in the United States and internationally. Top20English on Facebook now has over 700,000 followers.

In addition, one of the best ways to do well in school is to do some preparation before one takes a course. Like Clint Eastwood in a gunfight, you want an edge. You want to have the sun at your back. These free resources can be used to prepare for a course and as helpful supplemental material when taking a course. One’s first semester in college, for example, is by far the most important. It is thus prudent to take courses that one can do well in and to prepare ahead of time for those courses. Spending thirty minutes a day in the summer before college with these free resources would give one the edge of good preparation.

It is also possible at over 2000 colleges in the United States to get college credit by passing a CLEP or AP exam. A featured resource in the directory,, even offers free courses for self-study to pass the CLEP exams. Students can study for and take these exams to receive college credit and thus save time and money. That is particularly important for many international students. has a global perspective and thus all of the resources in these directories are open access or free. There are no paid inclusions. There is no tracking and selling of one’s information. The design is for a touch screen and requires no typing. There is an attempt to be family-friendly. There is a metasearch option provided as an alternative and an app directory for each topic as well. These curated directories were designed to be a guide by choosing just the best free resources for children, students, teachers, and adult learners.

Share article on social media or email:

Synthesizing Oligos Just Got Faster

Biolytic introduces the fastest, most efficient high throughput oligo synthesizer utilizing 2 x 384 well plates, the Dr. Oligo 768XLc.

Dr. Oligo 768XLc, the fastest, most efficient high throughput oligo synthesizer utilizing 2 x 384 well plates.

Biolytic’s novel patent pending system results is the highest possible chemical reaction efficiency

Biolytic Lab Performance, Inc. unveiled its novel oligo synthesizer, the Dr. Oligo 768XLc, the most commercially advanced platform for high throughput nucleic acid synthesis. Designed to be operated in both R&D and production facilities, it fits the needs of organizations focused on diagnostic and therapeutic applications for various viruses, diseases and conditions where large quantities of unique DNA and RNA are critical to their products, services and ongoing research.

Biolytic CEO and founder, Tom Demmitt, shared that the inspiration behind the Dr. Oligo 768XLc was to “accommodate industries innovating in diagnostic and therapeutic spaces and requiring state of the art oligos modified with non-standard bases.” Tom is confident that their new instrument will help Biolytic “play a crucial role in individualized medicine and immunotherapy worldwide.”

Ready to Run

The Dr. Oligo 768XLc includes fully tested protocols and initial 384-well synthesis media from 2 to 100 nmol per well for turn-key synthesis beginnings. Available with optional trityl collection, oligo desalting and elution capabilities.

Efficient Reactions

Biolytic’s novel patent pending system results is the highest possible chemical reaction efficiency using the minimum amount of reagents across our entire line of Dr. Oligo XLc instruments. Our system overcomes chemistry over consumption and reaction inconsistencies that are a result of well to well flow rate variability and other issues typical in high throughput synthesis media.


  • Extremely Efficient Mixing of all reagents dispensed into each well using our patent pending system. The entire volume of reagent delivered to each reaction well is thoroughly mixed with the synthesis media resulting in optimal use of all reagent delivered.
  • Deliver only the volume of each reagent needed to obtain the optimal molar excess for achieving near 100% reaction efficiency.
  • A simplified design and layout resulting in easier operation and maintenance thus lowering operational costs.
  • Innovative hardware designs result in efficiencies never before achieved in high throughput oligo synthesis. This translates to lowering cost of synthesis by conserving very costly unique bases / specials when synthesizing innovative, unique oligos.
  • A new, patent pending nozzle system dispenses 16 nozzles simultaneously and eliminates complexities of previously available designs. This results in reduces maintenance and operating cost as well as contributing to faster synthesis time.
  • Powerful Production Software providing the ability to efficiently synthesize complex molecules in high throughput while reducing consumption of costly modified nucleotide building blocks.

About Biolytic

Founded in 1993, Biolytic® Lab Performance, Inc. designs and manufactures the most advanced oligo synthesizers and related lab accessories in the world. Alongside more than 25 years of experience in end-to-end synthesis processes and equipment coupled with their extensive knowledge and customer support has allowed Biolytic to continuously lead the oligo synthesis industry.

Customers all over the world use oligos produced by Biolytic Dr. Oligo synthesizers for their own unique purposes. From applications like gene synthesis, genetic diagnostic test kits, PCR/RT – PCR, siRNA,/RNAi, miRNA, CRISPR Cas9, anti-sense treatments and DNA/RNA sequencing – to broader areas like evolutionary history, forensics, immunotherapy, diagnostic and therapeutic research – to high-throughput screening, modified oligos, mixed backbones, LNAs and the visual detection of virus RNA such as COVID-19 following RT-LAMP amplification with DNA primers – the variety is tremendous. The Dr. Oligo line has evolved alongside cutting-edge discoveries. Biolytic anticipates that the 768XLc will take its place to play a significant role in modern science.

Media Contact: Biolytic Lab Performance, Inc. – (510) 795-1142 – media [at] biolytic [dot] com

For more information please visit

Share article on social media or email:

Gateway Genomics Surpasses 200,000 SneakPeek Early Gender DNA Tests Sold with the Acceleration of At-Home Kit Purchases

SneakPeek Early Gender At-Home DNA Test

SneakPeek Early Gender At-Home DNA Test

In the current environment of physical distancing, SneakPeek At-Home provides families with an alternative way to learn their baby’s gender that’s perfectly suited to staying home and staying safe.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, reached 200,000 SneakPeek Early Gender DNA Tests sold in March, just months after attaining the 150,000-test landmark in late 2019.

SneakPeek was launched as an ecommerce product, where a mom could order her kit online, collect a DNA sample from her home, mail it back for analysis at our lab, and receive her emailed boy-or-girl result, all in days,” says Gateway Genomics CEO, Chris Jacob. “Direct-to-consumer is where the expertise of our company lies, and over the years we’ve optimized our product to be convenient and easy to use right at home. In the current environment of physical distancing, we’re grateful to be able to provide families with an alternative solution to learn the gender of their babies that’s perfectly suited to staying home and staying safe.”

The SneakPeek Test by Gateway Genomics analyzes cell-free fetal DNA found in mom’s blood to return just one answer – the gender of her unborn baby. This enables the test to use a very small amount of blood that can be collected at home. Results are emailed as fast as 72 hours after an order is placed online, with 99.1% accuracy for women who are at least 8 weeks into pregnancy, based on peer-reviewed studies.

“We understand this is a difficult situation and time, and not all families will want to or be able to visit their doctors to learn the fetal sex of their baby,” continues Mr. Jacob. “Our goal is to ensure that DNA-based prenatal information is accessible and affordable. In these uncertain times, we’re proud to deliver a product that gives parents the information they need to make plans, under their control. The SneakPeek Early Gender DNA Test provides a laboratory-proven at-home option to learn a baby’s gender and share the joy with family and friends.”

This year, Gateway Genomics was ranked #236 in the 38th annual Inc. 500|5000 list of fastest-growing private companies, #23 in the Health sector, in recognition of achieving 1,786% revenue growth in the last three years. The company’s principal product, SneakPeek, is an easy-to-use DNA test that lets parents know the gender of their babies as early as 8 weeks into pregnancy, with 99.1% accuracy.

About Gateway Genomics

Gateway Genomics is a personal genomics company with the mission to develop leading-edge genetic tests that give families a new level of understanding about their future children. Since inception, more than 200,000 SneakPeek Early Gender DNA tests have been provided to help new parents bond with their babies, make plans, and connect with friends and family around them. Gateway Genomics is located in La Jolla, CA.

Share article on social media or email:

Young Women In Bio (YWIB) Announces Launch of YWIB Ambassador Program; Postpones Annual Spring Into STEM™ Festival

News Image

“We are thrilled to launch our YWIB Ambassador Program at a time when an increasing number of girls see a future for themselves as leaders in STEM”

Young Women In Bio (YWIB) is pleased to announce the launch of its YWIB Ambassador Program. YWIB developed this new initiative for high school girls who are interested in championing and supporting YWIB’s efforts to create educational and leadership opportunities in science, technology, engineering, and math (STEM) for young girls, both locally and nationally.

YWIB invites high school girls to apply to become a Young Women In Bio (YWIB) Ambassador among its 13 chapters across the United States and in Canada. A YWIB Ambassador is a female student leader with a passion for STEM who demonstrates leadership among her peers by promoting STEM within her school, local community, and online and encouraging other girls in their quests to make a difference.

YWIB is excited to select YWIB Ambassadors for its inaugural program to launch during the 2020-2021 school year. YWIB Ambassadors will attend events and programs hosted by their local YWIB chapter and be actively engaged with YWIB to develop educational and other opportunities to fuel the passion for pursuing careers in STEM among young girls in their community, across the country, and in Canada. At the end of the school year, YWIB Ambassadors will be invited to apply for a scholarship that YWIB will award to the YWIB Ambassador who best exemplifies YWIB’s mission to empower today’s girls to become tomorrow’s leaders, helping them affect positive change in the worlds of science, technology,

engineering, and math.

“We are thrilled to launch our YWIB Ambassador Program at a time when an increasing number of girls see a future for themselves as leaders in STEM,” said Lily Wound, National Chair of YWIB. “We want to work directly with these high school girls to showcase their energy, enthusiasm, and creativity and to help them make a difference through their interest in STEM.”

Starting on May 1, 2020, YWIB will make YWIB Ambassador applications available on its webpage ( and provide guidelines for high school girls who are interested in applying to this program. Completed applications must be submitted to YWIB by June 15, 2020. Each of the 13 YWIB Chapters will then review applications from their local students and appoint one YWIB Ambassador for their region by August 15, 2020. Girls who are selected as YWIB Ambassadors will kick-off the program by Oct 15, 2020 and will continue their ambassadorship until the earlier of June 15, 2021, or through the end of their school year. YWIB will select a total of 13 Ambassadors (one for each chapter) for this inaugural year.

YWIB was originally going to launch its YWIB Ambassador Program during its annual Spring Into STEM™ Festival, now in its fourth year, which takes place from the first day of spring in March through the beginning of May. During the Spring Into STEM™ Festival, YWIB chapters and participating organizations across the United States and Canada invite girls from elementary school through high schools to a wide range of free events and activities, including company tours, panel discussions, and participation at major STEM festivals and conferences. However, given the growing number of social distancing mandates and restrictions on large events and other gatherings across the United States and Canada due to concerns regarding the spread of coronavirus, YWIB has decided to postpone its fourth annual Spring Into Festival™ and hopes to reschedule it for Fall 2020.


Young Women In Bio (YWIB) gives girls today the inspiration and support they need to become tomorrow’s leaders in science, technology, engineering, and math (STEM). We strive to provide education and hands-on experience in STEM, as well as share our passion for all scientific fields. Through 13 chapters across the United States and Canada, YWIB partners with leading companies, universities, hospitals, and other organizations to host highly engaging, educational, and motivational programs for young girls interested in STEM. To learn more, visit:


Founded in 2002 to support women employed in the field of life sciences from the classroom to the boardroom, Women In Bio (WIB) is a multifaceted organization with 13 chapters in North America. It offers an array of professional educational programs, peer to peer learning, mentoring and networking opportunities, and is the only organization for women that integrates all career levels and life sciences fields. WIB is funded by sponsors and partners dedicated to supporting women of all ages in their lifelong journey; in the life sciences and beyond. Please visit

For Immediate Release

Contact: Marsha Morgenstern

Women In Bio (WIB) Communication and Marketing Administrator


Share article on social media or email:

apexanalytix Recognized as Great Place to Work® for Third Consecutive Year

apexanalytix, the industry leader in technology and services to support the global financial supply chain, today announced it has been certified as a Great Place to Work® by independent analysts.

This is the third year in a row that the company has earned Great Place to Work credentials. Each year’s certification is based on extensive ratings from anonymous employee surveys and from a culture brief that details the company’s programs and practices.

In announcing their certification, Great Place to Work analysts highlighted several noteworthy results:

  • 97 percent say they feel good about the way the company contributes to the community.
  • 93 percent say individuals joining the company are made to feel welcome.
  • 91 percent say people are given a lot of responsibility.
  • 91 percent say the company’s facilities contribute to a good working environment.
  • 91 percent say special events are celebrated.

“We believe that making our company a great place to work gives us a true competitive advantage globally,” says Steve Yurko, CEO of apexanalytix. “We are able to attract and retain top talent, offer rewarding opportunities, and help our team deliver superior service to our customers.”

Lori Engebritson, SVP of Human Resources at apexanalytix agrees. “We’ve built an inclusive workplace where a diversity of opinion and background are highly valued, and where we care about each other, our community and our clients,” she says. “Ultimately, that sets us apart from our competitors in the marketplace.”

About Great Place to Work®

Great Place to Work® is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, including Best Workplaces lists and workplace reviews, Great Place to Work® provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. For more information, visit

About apexanalytix

apexanalytix revolutionized recovery audit with advanced analytics and the introduction of firststrike overpayment prevention software. Today, apexanalytix leads the world in supplier management innovation with apexportal and smartvm, the most popular supplier onboarding and compliant master data management solutions available. With over 250 clients in the Fortune 500 and Global 2000, apexanalytix is dedicated to providing companies and their suppliers the ultimate supplier management experience. Learn more at

Share article on social media or email:

Rigaku launches series of webinars to maintain productivity during downtime

TOPIQ Quick Webinars by Rigaku

TOPIQ Quick Webinars by Rigaku

The TOPIQ series of webinars will feature short presentations on a variety of topics related to X-ray fluorescence spectrometry, X-ray diffraction, and protein and small molecule X-ray crystallography, and include programs focusing on different applications and techniques.

Rigaku Corporation, a global leader in X-ray analytical instrumentation, is launching a new webinar series in the response to the extensive postponements and cancelations of global meetings and conferences resulting from the increasing spread of the coronavirus (COVID-19). The series is designed to accommodate those who are currently unable to attend live events, and offer alternative opportunities to access to information on the latest development in X-ray based analytical applications and technology.

The TOPIQ series of webinars will feature short presentations on a variety of topics related to X-ray fluorescence spectrometry, X-ray diffraction, and protein and small molecule X-ray crystallography, and include programs focusing on different applications and techniques. The series will offer presentations on several different subjects throughout the coming months.

The first TOPIQ webinar, Processing a PX Data Set With CrysAlisᴾʳᵒ, will take place on Friday, April 3, 2020 at 10:00 AM Central Standard Time. The presentation will focus on familiarizing users who are new to the CrysAlisᴾʳᵒ package with processing a protein crystallography data set using the software.

A schedule of upcoming webinars, with links to topic descriptions and event registration, is available at More details on the webinar series will be released as new events are added.

About Rigaku

Since its inception in Japan in 1951, Rigaku has been at the forefront of analytical and industrial instrumentation technology. Rigaku and its subsidiaries form a global group focused on general-purpose analytical instrumentation and the life sciences. With hundreds of major innovations to their credit, Rigaku companies are world leaders in X-ray spectrometry, diffraction, and optics, as well as small molecule and protein crystallography and semiconductor metrology. Today, Rigaku employs over 1,400 people in the manufacturing and support of its analytical equipment, which is used in more than 90 countries around the world supporting research, development, and quality assurance activities. Throughout the world, Rigaku continuously promotes partnerships, dialog, and innovation within the global scientific and industrial communities.

For further information, contact:

Michael Nelson

Global Marketing Coordinator

Rigaku Corporation

Share article on social media or email:

P2 Science and Bedoukian Research Announce Pheromones Collaboration

News Image

Bedoukian Research, Inc. (BRI) and P2 Science, Inc. (P2) announce the signing of a Joint Development Agreement that builds on each company’s expertise in developing efficient routes to synthesize insect pheromones.

Bedoukian Research, Inc. is a global leader in the supply of high-quality insect pheromones as well as flavors and fragrances. P2 has developed a suite of patented green chemistry process technologies that convert renewable feedstocks into high-value specialty chemicals. Under the terms of the JDA, the companies will bring these and other strengths together with the aim of developing business opportunities in the growing pheromone market utilizing plant-based, renewable chemicals.

“Bedoukian Research, Inc. has been manufacturing insect pheromones since 1975, obtaining numerous global technical pheromone active ingredient registrations, concentrated mainly in the United States, Canada and Europe,” said Robert Bedoukian, CEO of Bedoukian. “BRI is dedicated to innovative solutions for challenging market segments and advocates these issues as an active member of both the Biological Products Industry Alliance (BPIA) as well as the International Biocontrol Manufacturers Association (IBMA). Bedoukian Research, Inc. and P2 Science together support safe, effective, and more economical solutions for pest management and crop protection, as well as the development of novel, renewable chemical ingredients.

“P2 was founded on the principle of minimizing harm to the planet and its people, while at the same time providing the highest performing chemical products to our customers,” said Neil Burns, CEO of P2. “Our partnership with BRI brings together two like-minded companies with complementary skills and abilities. We are really excited to be launching this new intiative with them.

About Insect Pheromones:

Pheromones act as chemical messages that affect the behavior of an individual or group of individuals within the same species and can be used as a method of communication between members of the same or the opposite sex. Insect pheromones are essential components of monitoring and management tools targeting pests of agricultural crops. Mating disruption, mass trapping, “attract-and-kill”, and “push-pull” are some of the direct pest control strategies that have utilized the use of pheromones for over three decades.

About Bedoukian Research, Inc.:

Bedoukian Research was founded in 1972 by Dr. Paul Bedoukian to fill a niche as a supplier of high-quality specialty aroma and flavor ingredients. Paul Bedoukian’s son, Dr. Robert Bedoukian, joined the company in 1975. At that time, the company began manufacturing insect pheromones, which are chemically similar to flavor and fragrance ingredients. Today, Bedoukian Research offers more than 450 Aroma Chemicals and 50 Insect Pheromones, while also providing custom manufacturing services to the pharmaceutical, agrochemical, and specialty chemical industries. For more information, see

About P2 Science, Inc.:

P2 Science is renewable chemistry company. The co-founders of P2, Professor Paul Anastas and Dr. Patrick Foley, worked together at the Yale Center for Green Chemistry and Green Engineering. P2 has developed and patented green chemistry technologies for converting renewable feedstocks into high-value specialty products. Investors in P2 include BASF Venture Capital, Xeraya Capital, Elm Street Ventures, Connecticut Innovations, Ironwood Capital, HG Ventures and Chanel. The company started up its first manufacturing plant in September of 2018 which produces novel renewable aroma chemicals and cosmetics ingredients. For more information, see

Media Contact:

Neil Burns

Share article on social media or email:

Carterra® Inc. Selected by the La Jolla Institute of Immunology to Provide Antibody Screening and Characterization for the Coronavirus Immunotherapy Consortium (CoVIC)

The world is in need of a solution to COVID-19.


The world is in need of a solution to COVID-19. We’re honored to be the provider of high-throughput antibody screening and characterization data to CoVIC. They have the most ambitious research goals and aggressive timelines. The Carterra LSA is the right tool at the right time.

Carterra® Inc., the world leader in high-throughput antibody screening and characterization tools, and La Jolla Institute for Immunology (LJI), announced today that they will use Carterra’s proprietary LSA™ platform to screen hundreds of antibodies in just a few days allowing CoVIC to move therapeutic candidates to the clinic as early as this summer.

La Jolla Institute for Immunology (LJI) has been awarded a $1.73 million grant by the Bill & Melinda Gates Foundation to establish a Coronavirus Immunotherapy Consortium (CoVIC) as part of the foundation’s global efforts to stem the tide of the current coronavirus outbreak, the Institute announced yesterday. Antibody therapies are often the first novel therapies advanced for an emerging infectious disease.

Headquartered at LJI, CoVIC will serve as a clearinghouse to understand which antibodies are most effective against the novel coronavirus SARS-CoV-2 and to accelerate the research pipeline to provide immunotherapeutics in order to protect vulnerable individuals from severe manifestations of COVID-19 in all parts of the world including low-resource settings.

This effort is being funded as part of the COVID-19 Therapeutics Accelerator launched in early March by the Gates Foundation, Wellcome, and Mastercard. The Accelerator provides fast and flexible funding at key stages of the development process to de-risk the pathway for drugs and biologics to prevent and treat COVID-19.

The effort is led by Erica Ollmann Saphire, Ph.D., a professor in LJI’s Center for Infectious Disease and Vaccine Research, who draws on her broad research experience guiding the development of antibody drugs and galvanizing a global research coalition that helped define which therapeutic antibodies effectively combat disease in humans infected with Ebola virus.

“We are thrilled that Carterra will provide full antibody characterization data using affinity measurements and, potentially more importantly, ultra-high resolution information of the epitopes,” says Dr. Ollmann Saphire. “Knowing how well these antibodies bind to the target is important but understanding their mechanism of action and how different antibodies can complement each other will determine what ends up in the clinic.”

Traditional antibody discovery requires a primary screen of ever-expanding antibody libraries. Only a small group of candidate antibodies are then characterized on traditional, low-throughput, low-resolution biosensor tools which provide real-time readout of the binding profile. This workflow runs the risk that potential drug candidates could be missed or that the process of candidate selection could be exceedingly long.

Carterra’s LSA is turning that model on its head by enabling the high-resolution analysis of entire libraries, combining screening and characterization into one seamless step, thereby minimizing the risk of missing a potent therapeutic candidate. The LSA’s dramatic throughput condenses months of work into days. Infectious diseases are ideal for leveraging the power of the LSA platform as evidenced in recent studies of Yellow Fever and Ebola where the LSA helped elucidate the immunity of survivors.

Additionally, the LSA platform offers investigators the most resolved view of the epitope – the location an antibody binds to its target. An epitope is an innate property that cannot be changed and must be discovered empirically. The LSA is the only technology that enables characterization of epitope binding at the full library level.

“The world is in need of a solution to COVID-19,” says Josh Eckman, Carterra’s Chief Executive Officer. “We’re honored to be the provider of high-throughput antibody screening and characterization data to CoVIC. They have the most ambitious research goals and aggressive timelines. The Carterra LSA is the right tool at the right time.”

About Carterra, Inc.

Carterra® is the leading provider of high throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA™ instrument, software, and consumables for monoclonal antibody (mAb) characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. Carterra, Inc. is based in Salt Lake City Utah, and has Customer Experience Centers in Dublin, California, Boston, Massachusetts, and Munich, Germany. For additional information, please visit:

About La Jolla Institute for Immunology

La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading towards its goal: life without disease®.

Share article on social media or email:

Mount Sinai Researchers Discover Potential Boost to Cancer Immunotherapy

Mount Sinai researchers have discovered a pathway that regulates special immune system cells in lung cancer tumors, suppressing them and allowing tumors to grow. The scientists also figured out how to interrupt this pathway and ramp up the immune system to prevent tumor formation or growth, offering a potential boost to immunotherapy, according to a study published in Nature in March.

Researchers analyzed human and mouse lung cancer lesions, specifically studying the highly specialized immune cells called dendritic cells, which are considered the generals of the immune system. Dendritic cells give other immune system cells, called T-cells, identifying information from tumors so the T-cells can recognize and fight the cancer. Certain genetic material in the tumors, however, tamps down the dendritic cells’ function via this newly discovered immune regulatory pathway.

Scientists performed high-tech, single-cell sequencing and high-definition imaging on mouse and human tumors to study the dendritic cells’ activity in lung cancer and adjacent noncancerous lung tissues. They identified a molecular pathway that dampens dendritic cells’ ability to program T-cells to kill. This study also showed that reversing this pathway significantly improves tumor responses in animals.

Based on the findings, scientists are designing a clinical trial that they expect will enhance patients’ response to an immunotherapy called checkpoint blockade, by adding a second therapy that blocks the immune regulatory pathway that decreases dendritic cells’ function in tumors. Right now only about 20 percent of patients respond to checkpoint blockade therapies. The trial will be done in collaboration with Regeneron Inc.

“This study highlights the power of single-cell technologies to identify new therapeutic targets in cancer,” said senior author Miriam Merad, MD, PhD, Director of the Precision Immunology Institute and Mount Sinai Professor in Cancer Immunology at the Icahn School of Medicine at Mount Sinai, Co-leader of the Cancer Immunology Program at The Tisch Cancer Institute at Mount Sinai, and Director of the Mount Sinai Human Immune Monitoring Center.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.

For more information, visit or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email: